Today: 8 February 2026
Subscribe
Browse Category

NASDAQ:RAPT News 20 January 2026 - 22 January 2026

GSK share price steadies as $2.2bn RAPT deal lands amid fresh U.S. vaccine-policy risk

GSK share price steadies as $2.2bn RAPT deal lands amid fresh U.S. vaccine-policy risk

GSK shares rose 0.1% in early London trading as investors assessed the $2.2 billion acquisition of RAPT Therapeutics and changes to ViiV Healthcare’s ownership. The deal brings ozureprubart, a mid-stage food-allergy drug, into GSK’s pipeline. Pfizer will exit ViiV, with Shionogi raising its stake to 21.7%. Uncertainty over U.S. vaccine policy clouds the outlook ahead of GSK’s Feb. 4 results.
22 January 2026
···
GSK stock slips after $2.2 billion RAPT deal — what investors watch before the open

GSK stock slips after $2.2 billion RAPT deal — what investors watch before the open

GSK’s U.S.-listed shares fell 1.2% to $47.65 premarket after it agreed to buy RAPT Therapeutics for $2.2 billion, paying a 65% premium for rights to a mid-stage food allergy drug. The deal, led by new CEO Luke Miels, comes as GSK faces pressure to offset losses from expiring HIV drug patents. Pfizer will exit the ViiV Healthcare joint venture, with Shionogi raising its stake to 21.7%.
21 January 2026
···
RAPT Therapeutics stock jumps 64% as GSK agrees $2.2 billion takeover at $58 a share

RAPT Therapeutics stock jumps 64% as GSK agrees $2.2 billion takeover at $58 a share

Rapt Therapeutics shares surged 64% to $57.57 in after-hours trading after GSK agreed to acquire the company for $58 a share in cash, valuing Rapt at about $2.2 billion. The deal centers on ozureprubart, a long-acting anti-IgE antibody. GSK plans to launch a tender offer within 10 business days. Closing depends on a majority of Rapt shares being tendered and U.S. antitrust clearance.
21 January 2026
···
RAPT stock price jumps as GSK strikes $2.2 billion buyout for food allergy drug

RAPT stock price jumps as GSK strikes $2.2 billion buyout for food allergy drug

RAPT Therapeutics shares soared 64% to $57.54 after GSK announced a $58-per-share cash acquisition, valuing the biotech at $2.2 billion. The deal centers on ozureprubart, an experimental anti-IgE drug for food allergies. GSK plans to launch a tender offer within 10 business days, pending antitrust review. RAPT’s stock hovered just below the offer price as investors watched for regulatory developments.
20 January 2026
···

Stock Market Today

MediaTek stock price drops 3.4% as Taiwan market shuts; what investors watch next week

MediaTek stock price drops 3.4% as Taiwan market shuts; what investors watch next week

8 February 2026
MediaTek shares closed down 3.4% at NT$1,710 on Friday in Taipei, with 11.8 million shares traded before the market shut for the weekend. The company said it will double investment in data-center chips and advanced packaging, while warning of rising supply chain costs. Fourth-quarter sales rose 8.8% to NT$150.2 billion, but net income slipped 3.6%. Investors face uncertainty ahead of the Lunar New Year break and a weaker tech sector mood.
Arm Holdings stock rallies into weekend on AI spending hopes — Monday’s next test

Arm Holdings stock rallies into weekend on AI spending hopes — Monday’s next test

8 February 2026
Arm Holdings’ U.S. shares jumped 11.6% Friday to $123.70, capping an 18% two-day rebound amid a rally in chip stocks tied to AI data-center spending. The gains followed Arm’s fiscal Q3 revenue beat, but executives warned memory shortages could cut royalty revenue by up to 2% as smartphone chip shipments are expected to fall 7% in 2026. Investors now await Arm’s “Arm Everywhere” event on March 24.
Zhongji Innolight stock slides nearly 4% into China’s Monday open — what traders watch next

Zhongji Innolight stock slides nearly 4% into China’s Monday open — what traders watch next

8 February 2026
Zhongji Innolight closed down 3.9% at 540.01 yuan in Shenzhen on Friday, with turnover at 17.91 billion yuan. The company forecast 2025 net profit of 9.8–11.8 billion yuan, up as much as 128%, citing strong demand for high-speed products. Executives said most customer orders are booked through late 2026, but flagged tight supply of some optical chips. Zhongji reports earnings March 31 after shares dropped 12% from December highs.
Go toTop